An advisory panel to the FDA voted to recommend the agency approve the sale of a knockoff version of J&J’s arthritis drug Remicade, which had U.S. sales of $4.45 billion last year. The copy was developed by Celltrion and licensed to Pfizer.
French drugmaker Sanofi has ended a licensing pact with MannKind for the rights to sell Afrezza, saying the insulin inhaler for diabetes care was unlikely to reach even the lowest patient levels anticipated.
Canadian Pacific Railway has abandoned its threat of a proxy battle to replace directors at takeover target Norfolk Southern, opting instead for a less confrontational strategy of seeking shareholder support for friendly merger talks.
Boss Talk: Whole Foods Markets has spent much of the past year fighting slower growth and negative headlines. In an interview, co-CEO Walter Robb discusses its candid culture and what’s ahead for the grocery business.